ONCOLYTICS BIOTECH INC. (ONC.TO) ANNOUNCES ISSUANCE OF 2ND EUROPEAN PATENT

Oncolytics Biotech Inc. ("Oncolytics") has been granted European Patent 1,309,672 entitled "Method of Producing Infectious Reovirus." The claims relate to a method of producing infectious mammalian reovirus which is suitable for clinical administration to mammals including humans. "This patent is consistent with our strategy to continue to expand and strengthen our portfolio of intellectual property worldwide," said Dr. Matt Coffey, Chief Scientific Officer for Oncolytics. "Along with our clinical trial and collaborative research programs in Europe, the United States and Canada, these patents are a key component of our development strategy for REOLYSIN(R)."

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=20625620&full=1)